Prosecution Insights
Last updated: October 27, 2026

Mark V Stevens, USPTO Patent Examiner

Listed by the USPTO as STEVENS, MARK V

Tech Center 1600 • Art Units: 1600 1613 1646 1655

This examiner grants 66% of resolved cases

Analysis

STEVENS, MARK V is assigned to Tech Center 1600 and Art Unit 1600. His profile covers 875 resolved cases and reports a 65.5% allowance rate. The interview lift is 41.6%, and the median time to allowance is 976 days. The record supports a meaningful assessment of prosecution behavior, with interviews showing a substantial positive association alongside a majority allowance rate.

The principal companies are Genexa Inc., Sigilon Therapeutics Inc., and Antecip Bioventures Ii LLC. The listed firms are HESLIN ROTHENBERG FARLEY & MESITI PC, MH2 TECHNOLOGY LAW GROUP, LLP, and BakerHostetler. Applicants can consider early interview preparation while using the median timing measure to structure prosecution budgets and portfolio forecasts.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

65.5%
Allow Rate
+5.5% vs TC avg
944
Total Applications
+41.6%
Interview Lift
976
Avg Prosecution Days
Based on 875 resolved cases, 2023–2026

Rejection Statute Breakdown

5.1%
§101 Eligibility
11.7%
§102 Novelty
39.8%
§103 Obviousness
23.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18517448 ANTI-TUMOR AGENT Non-Final OA FUJIFILM Corporation
18572884 COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES Final Rejection The Regents of the University of Michigan
18911341 ORAL CARE COMPOSITIONS COMPRISING DICARBOXYLIC ACID Non-Final OA The Procter & Gamble Company
18570690 BIOMATERIALS COATING FOR ON-DEMAND BACTERIA DELIVERY AND METHOD TO TREAT COLITIS AND IRRITABLE BOWEL SYNDROME Final Rejection Wisconsin Alumni Research Foundation
18169695 HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING Final Rejection The General Hospital Corporation
18870231 HERBICIDAL DERIVATIVES Non-Final OA SYNGENTA CROP PROTECTION AG
18293204 POLYMER NANOPARTICLES VIA CONDENSED DROPLET POLYMERIZATION Final Rejection CORNELL UNIVERSITY
18642331 MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION Final Rejection Senseonics, Incorporated
18738288 Zinc Phosphate Complex Final Rejection Colgate-Palmolive Company
18697938 Selenium Containing Antimicrobial Compound as a Reacitve Dye and Cross-Linking Treatment for Textile Applications Non-Final OA Texas Tech University System
18747164 MICROWAVE ASSISTED EXTRACTION OF ESSENTIAL OILS FROM PLANT BIOMASS Final Rejection Firmenich SA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Mark V Stevens's allowance rate?

65.5% of resolved applications examined by Mark V Stevens were allowed (875 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.

Does an interview help with examiner Mark V Stevens?

This examiner's interview lift is +41.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Mark V Stevens take to allow a patent?

Applications allowed by Mark V Stevens took 976 days on average from filing to allowance.

Which art unit does examiner Mark V Stevens work in?

Mark V Stevens examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month